Site icon pharmaceutical daily

Global Influenza Clinical Trial Pipeline Highlights 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Influenza Clinical Trial Pipeline Highlights – 2020” report has been added to ResearchAndMarkets.com’s offering.

This report provides the most up-to-date information on key pipeline products in the global Influenza market. It covers emerging therapies for Influenza in active clinical development stages including early and late-stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Influenza pipeline products by clinical trial stages including both early and late-stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Influenza pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Influenza pipeline products by company.

Short-term Launch Highlights:

Find out which Influenza pipeline products will be launched up to 2025.

Key Topics Covered:

For more information about this report visit https://www.researchandmarkets.com/r/2kdip8.

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version